Differences in total medical costs across the SSRIs for the treatment of depression and anxiety

American Journal of Managed Care

Volumn 11, Issue SUPPL. 12, 2005, Pages

  Sheehan, David V ^a   Eaddy, Michael T ^a   Shah, Manan B ^a   Mauch Jr , Robert P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANXIETY DISORDER; ARTICLE; COMORBIDITY; CONTROLLED DRUG RELEASE; COST BENEFIT ANALYSIS; DEPRESSION; DRUG COST; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANXIETY DISORDERS; BENCHMARKING; COMORBIDITY; DATABASES; DEPRESSIVE DISORDER; DRUG UTILIZATION REVIEW; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 27544495523     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kessler RC, Berglund PA, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
2. Arikian SR, Gorman JM. A review of the diagnosis, pharmacologic treatment, and economic aspects of anxiety disorders. Prim Care Companion J Clin Psychiatry. 2001;3:110-117.
3. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-1475.
4. IMS Health. IMS reports 11.5% dollar growth in 2003 US prescription sales. Available at: www.imshealth.com. Accessed October 29, 2004.
5. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:653-661.
6. Claxton AJ, Li Z, McKendrick J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry. 2000;177:163-168.
7. Eaddy M, Sarnes M, Regan T, Mauch R. Examining the relationship between length of selective serotonin reuptake inhibitor treatment and the risk of hospitalization in a naturalistic managed care setting. Poster presented at: the Academy of Managed Care Pharmacy Educational Conference; October 13-16, 2004; Baltimore, Md.
8. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to cost of care. Am J Manag Care. 1996;2:1239-1246.
9. Karasu TB, Gelenberg A, Merriam A, Wang P. Practice Guidelines for the Treatment of Patients With Major Depressive Disorder. 2nd ed. Arlington, Va: American Psychiatric Publishing, Inc; 2000.
10. Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum LE. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy-results from a managed care administrative claims database. J Manag Care Pharm. 2005;11:145-150.
11. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002;36:578-584.
12. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33:67-74.
13. Eaddy M, Bramley T, Regan T. Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors. Manag Care Interface. 2003;16:22-27.
14. Keene MS, Eaddy MT, Mauch RP, Regan TS, Shah M, Chiao E. Differences in compliance patterns across the selective serotonin reuptake inhibitors for the treatment of depression and anxiety. Curr Med Res Opin. 2005;21:1651-1658.
15. Sheehan DV, Eaddy M, Sarnes M, Vishalpura T, Regan T. Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine. J Clin Psychopharmacol. 2004;24:544-548.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
18. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283-295.
19. Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs. 2004;18:911-932.
20. Sheehan D, Chiao E, Eaddy M, Shah M, Sarnes M. Differences in patterns of therapy change across the selective serotonin reuptake inhibitors (SSRIs) for treatment of depression and anxiety. Drug Benefit Trends. 2005;17:403-410.
21. Rost K, Smith R, Matthews DB, Guise B. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med. 1994;3:333-337.